Genmab A/S announced today that its partner, Roche has initiated a Phase II clinical study of R1507 for the treatment of recurrent or refractory sarcoma
COPENHGAEN, Denmark | December 20, 2007 | Genmab A/S (OMX: GEN) announced today that its partner, Roche has initiated a Phase II clinical study of R1507 for the treatment of recurrent or refractory sarcoma The R1507 antibody was created by Genmab under the company’s agreement with Roche and initiation of the trial will trigger a milestone payment to Genmab of USD 500,000.
“R1507 will be the first antibody created by Genmab under our agreement with Roche to enter Phase II development,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. “We believe that R1507 may offer an additional treatment option to sarcoma patients.”
About Sarcoma
Sarcoma is a cancer of the connective tissue including muscle, bone, fat, nerve, cartilage, blood vessel and deep skin tissue. Due to the wide variety of types of sarcoma, the disease is often difficult to detect, is often misdiagnosed and is complex to treat. Sarcoma is a rare type of cancer with US incidence of approximately 9,000 to 11,000 new cases per year. Of these approximately 8,000 are cases of soft tissue sarcoma and 2,000 are sarcoma of the bone.
SOURCE: Genmab
Post Views: 125
Genmab A/S announced today that its partner, Roche has initiated a Phase II clinical study of R1507 for the treatment of recurrent or refractory sarcoma
COPENHGAEN, Denmark | December 20, 2007 | Genmab A/S (OMX: GEN) announced today that its partner, Roche has initiated a Phase II clinical study of R1507 for the treatment of recurrent or refractory sarcoma The R1507 antibody was created by Genmab under the company’s agreement with Roche and initiation of the trial will trigger a milestone payment to Genmab of USD 500,000.
“R1507 will be the first antibody created by Genmab under our agreement with Roche to enter Phase II development,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. “We believe that R1507 may offer an additional treatment option to sarcoma patients.”
About Sarcoma
Sarcoma is a cancer of the connective tissue including muscle, bone, fat, nerve, cartilage, blood vessel and deep skin tissue. Due to the wide variety of types of sarcoma, the disease is often difficult to detect, is often misdiagnosed and is complex to treat. Sarcoma is a rare type of cancer with US incidence of approximately 9,000 to 11,000 new cases per year. Of these approximately 8,000 are cases of soft tissue sarcoma and 2,000 are sarcoma of the bone.
SOURCE: Genmab
Post Views: 125
